Latest Tacro Stories

2011-06-21 04:10:00

HORSHOLM, Denmark, June 21, 2011 /PRNewswire/ -- LifeCycle Pharma A/S (OMX:LCP) today reported that the company's lead product candidate, LCP-Tacro(TM), successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III trial, Study 3001. The Phase III Open-label conversion (switch) study in 326 stable kidney transplant recipients, with Prograf® as the comparator, met its primary efficacy and primary safety...

2011-01-06 06:00:00

HORSHOLM, Denmark, Jan. 6, 2011 /PRNewswire/ -- LifeCycle Pharma A/S (OMX: LCP) has announced positive top-line results from a Phase 2 clinical trial involving 58 patients comparing LCP-Tacro(TM) tablets administered once-daily versus Prograf® (tacrolimus) capsules (Astellas Pharma) administered twice-daily in de novo liver transplant patients for one year. These data confirm the previous positive experience with LCP-Tacro(TM) in stable kidney and liver transplant patients...

Word of the Day
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'